C
EW icon

Cerebellum’s Edwards Lifesciences EW Stock Holding History

Cerebellum’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,135
Closed -$128K – 448
2020
Q2 		$128K Buy
+1,135
New +$80.7K 0.09% 167
2019
Q4 		$522K Buy
6,717
+621
+10% +$48.5K 0.28% 272
2019
Q3 		$447K Buy
6,096
+2,721
+81% +$191K 0.29% 110
2019
Q2 		$208K Buy
+3,375
New +$204K 0.17% 346
2018
Q2 		– Sell
-4,008
Closed -$186K – 447
2018
Q1 		$186K Buy
4,008
+603
+18% +$26.2K 0.24% 179
2017
Q4 		$128K Buy
+3,405
New +$125K 0.09% 167

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cerebellum's EW Position: Q3 2020 in Review

Cerebellum sold out of Edwards Lifesciences (EW) in Q3 2020, closing a stake of 1,135 shares — an estimated $128K sold.

Cerebellum first reported a position in EW in Q4 2017 and held it in 6 quarters. The position peaked at $522K in Q4 2019. 1,083 funds tracked by Wall St. Rank hold EW as of Q3 2020.

  • Cerebellum reported no remaining Edwards Lifesciences position as of Q3 2020 after selling out during the quarter.
  • Cerebellum sold 1,135 Edwards Lifesciences shares in Q3 2020, an estimated $128K.
  • Cerebellum first reported a position in Edwards Lifesciences in Q4 2017 and held it in 6 quarters.
  • Cerebellum's Edwards Lifesciences position peaked at $522K in Q4 2019.
  • 1,083 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2020.

Based on Cerebellum's 13F filing for Q3 2020, filed 21 Oct 2020.